CLDX — CELLDEX THERAPEUTICS INC NEW

Ownership history in GUGGENHEIM CAPITAL LLC  ·  4 quarters on record

This page tracks every 13F SEC filing in which GUGGENHEIM CAPITAL LLC reported a position in CELLDEX THERAPEUTICS INC NEW (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 22,721 -3,274 -12.6% 0.00% $588K $25.87
2025 Q2 ADDED 25,995 +1,212 +4.9% 0.00% $529K $20.35
2025 Q1 ADDED 24,783 +986 +4.1% 0.00% $450K $18.15
2024 Q4 INITIATED 23,797 — — 0.00% $601K $25.27
% of Fund (quarterly)    CLDX price (monthly, adj. close)

Other funds also holding CLDX

As of 2025 Q4 — sorted by position size

Kynam Capital Management, LP 3Y 10.31% Elmind Capital, LP 6.93% Commodore Capital LP 3Y 4.64% 5AM Venture Management, LLC 3Y 4.25% Propel Bio Management, LLC 3.58% GordonMD Global Investments LP 3.32% Novo Holdings A/S 3Y 7Y 2.53% TSP Capital Management Group, LLC 3Y 7Y 2.49% Eversept Partners, LP 3Y 7Y 1.96% Bellevue Group AG 3Y 7Y 1.86%
← Back to GUGGENHEIM CAPITAL LLC Holdings